Clinical trial
A Controlled Study of Olanzapine in Children With Autism
NCT00057408 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00057408 |
|---|---|
| Title | A Controlled Study of Olanzapine in Children With Autism |
| Official title | A Controlled Study of Olanzapine in Children With Autism |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Autistic Disorder |
| Intervention type | Drug |
| Interventions | olanzapine (Zyprexa), Placebo |
| Enrollment | 78 |
| Start date | May 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Apr 2, 2003 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: